List of Excipients in Branded Drug NITROFURANTOIN ORAL SUSPENSION

Generic Drugs Containing NITROFURANTOIN ORAL SUSPENSION

Company	Ingredient	NDC	Excipient
PAI Holdings LLC dba PAI Pharma	nitrofurantoin oral suspension	0121-1996	ANHYDROUS CITRIC ACID
PAI Holdings LLC dba PAI Pharma	nitrofurantoin oral suspension	0121-1996	CARBOXYMETHYLCELLULOSE SODIUM
PAI Holdings LLC dba PAI Pharma	nitrofurantoin oral suspension	0121-1996	GLYCERIN

What are the Most Frequently-Used Excipients in NITROFURANTOIN ORAL SUSPENSION?

# Of NDCs	Excipient
1	ANHYDROUS CITRIC ACID
1	CARBOXYMETHYLCELLULOSE SODIUM
1	GLYCERIN

Nitrofurantoin Oral Suspension Excipient Strategy and Commercial Opportunities

Last updated: September 5, 2026

Nitrofurantoin oral suspension is a mature, prescription antibacterial product with limited active-ingredient patent protection and meaningful formulation barriers. The strongest commercial opportunities are pediatric and dysphagia-friendly dosing, pharmacy availability, unit-dose packaging, improved taste, and reliable resuspension. The principal technical risks are nitrofurantoin’s poor water solubility, dose uniformity, sedimentation, chemical stability, palatability, and compatibility with administration devices.

What is nitrofurantoin oral suspension?

Nitrofurantoin oral suspension is an immediate-release liquid formulation used for the treatment or suppression of urinary tract infections caused by susceptible organisms. The established U.S. product Furadantin is supplied as a 25 mg/5 mL oral suspension and is administered orally with food or milk to improve absorption and gastrointestinal tolerance (FDA, 2024a).

Nitrofurantoin is a small-molecule antibacterial that has been marketed for decades. The oral suspension is differentiated from capsule products such as Macrobid and Macrodantin by its liquid dosage form, concentration, dosing flexibility, and suitability for patients who cannot swallow solid dosage forms.

Product characteristic	Nitrofurantoin oral suspension
Active ingredient	Nitrofurantoin
Strength	25 mg/5 mL
Dosage form	Immediate-release oral suspension
Route	Oral
Primary use	Urinary tract infection
U.S. reference product	Furadantin oral suspension
Regulatory pathway for follow-on products	ANDA or potentially 505(b)(2), depending on product design
Biosimilar exposure	None; nitrofurantoin is a small molecule
Key technical issue	Uniform delivery of an insoluble, taste-sensitive drug

What excipients are used in nitrofurantoin oral suspension?

The established formulation uses a structured aqueous vehicle containing suspending, wetting, buffering, sweetening, and flavoring components. The Furadantin label identifies inactive ingredients including carbomer, citric acid, flavor, polysorbate 80, sodium citrate, sorbitol, and xanthan gum (FDA, 2024a).

The formulation strategy has five functional objectives:

Excipient function	Typical role
Suspending agent	Keeps nitrofurantoin particles dispersed during storage
Wetting agent	Reduces interfacial tension and improves powder incorporation
Rheology modifier	Controls sedimentation and supports dose uniformity
Buffer	Maintains product pH and supports chemical stability
Sweetener and flavor	Reduces bitterness and improves patient acceptance
Preservative system	Controls microbial growth in a multidose aqueous product
Chelator or antioxidant, if required	Limits metal-catalyzed degradation

Carbomer and xanthan gum create a structured vehicle that slows sedimentation. Sodium citrate and citric acid provide buffering capacity. Polysorbate 80 assists wetting and dispersion of hydrophobic drug particles. Sorbitol contributes sweetness and mouthfeel while increasing soluble solids.

The excipient system must remain compatible with the particle-size distribution of nitrofurantoin. A high-viscosity vehicle can improve physical stability but may create dosing problems, poor pourability, syringe resistance, and residual drug retention on the container wall.

How should an excipient platform be designed for nitrofurantoin suspension?

The preferred development strategy is a low-to-moderate viscosity suspension with rapid redispersion and a controlled sedimentation profile. The product should form a loose sediment rather than a compact cake. It must redisperse after ordinary shaking and deliver a consistent dose throughout the labeled in-use period.

Suspending system

Carbomer, xanthan gum, microcrystalline cellulose with carboxymethylcellulose, hydroxypropyl methylcellulose, and sodium carboxymethylcellulose are potential suspending systems. Each produces different rheological behavior.

Carbomer can provide strong suspension performance at low concentration but is sensitive to pH, ionic strength, and neutralization. Xanthan gum is more tolerant of salts and acidic conditions but can produce stringiness or an undesirable mouthfeel. Cellulose-based systems can improve pourability but may require higher concentrations.

The commercial target is not maximum viscosity. It is dose uniformity after storage, acceptable syringeability, and rapid redispersion with a defined number of shakes.

Wetting and dispersion

Nitrofurantoin’s limited aqueous solubility makes wetting and deagglomeration central to manufacturing. Polysorbate 80 is used in the reference formulation and may support particle wetting. Other surfactants could affect taste, foam generation, preservative performance, and gastrointestinal tolerability.

Drug particle engineering may create a stronger competitive position than excipient substitution alone. Controlled milling, narrow particle-size distribution, and removal of oversized agglomerates can reduce sedimentation variability and improve content uniformity.

Sweetening and flavoring

Nitrofurantoin has an inherently difficult taste profile. Sorbitol is useful for sweetness and body but can cause gastrointestinal effects at higher exposure. Sucrose may improve palatability but increases dental, caloric, and microbial-control considerations. High-intensity sweeteners such as sucralose or acesulfame potassium could reduce solids loading but may leave a bitter or lingering aftertaste.

Flavor selection should be tested in the presence of the complete formulation. A flavor that performs well in a placebo may fail after addition of nitrofurantoin because the drug can dominate the sensory profile.

Preservative strategy

A multidose aqueous suspension requires an effective antimicrobial preservation system unless the product is packaged as sterile unit doses. Preservative efficacy depends on pH, surfactant binding, container adsorption, and interaction with polymeric packaging.

Parabens, benzoate systems, and other preservatives require compatibility testing with the selected vehicle and container. The target product should pass antimicrobial effectiveness testing under applicable pharmacopeial standards and maintain preservative performance through the labeled in-use period.

What formulations are protected by nitrofurantoin patents?

The active ingredient is an old small molecule, so the primary commercial opportunity is not based on new-molecule exclusivity. Protection would more likely arise from formulation composition, particle engineering, manufacturing processes, packaging, or a specific delivery system.

Potential protection area	Commercial relevance
Novel suspending system	May support formulation patent protection
Taste-masking technology	Could protect pediatric or dysphagia positioning
Controlled particle-size distribution	May support process or composition claims
Ready-to-administer unit dose	Could support packaging and dosing claims
Feeding-tube-compatible formulation	May support device-use or formulation claims
Extended in-use stability	May improve pharmacy and institutional use
Reconstitutable powder	Could reduce shipping and stability burdens
Modified-release liquid	Could create a differentiated product but raises regulatory complexity

A conventional suspension using known excipients is unlikely to create a strong patent position unless it produces unexpected stability, palatability, bioavailability, dose uniformity, or administration results. Freedom-to-operate work should focus on active formulation patents, excipient combinations, particle-size claims, filling methods, dosing devices, and packaging patents.

What is the FDA regulatory status of nitrofurantoin oral suspension?

Furadantin is an FDA-approved prescription oral suspension. The product is listed as nitrofurantoin oral suspension USP, 25 mg/5 mL, and carries labeling for susceptible urinary tract infections (FDA, 2024a).

The regulatory route depends on the degree of similarity to the reference product:

ANDA strategy

An ANDA is the most direct route for a product that matches the reference listed drug in active ingredient, dosage form, strength, route, and labeling, subject to applicable pharmaceutical equivalence and bioequivalence requirements. A generic applicant would need to address:

• Assay and content uniformity
• Particle-size distribution
• Redispersibility
• Viscosity and rheology
• Dissolution or drug-release behavior, where applicable
• Microbial limits
• Preservative effectiveness
• Container-closure integrity
• Stability and in-use performance
• Comparative bioequivalence or other FDA-requested studies

For a suspension, comparative formulation and in vitro characterization can be more demanding than for a simple solution. FDA may focus on particle size, viscosity, sedimentation, redispersibility, and the relationship between in vitro performance and clinical exposure.

505(b)(2) strategy

A 505(b)(2) application may be appropriate for a materially different formulation, such as a novel taste-masked suspension, unit-dose system, reconstitutable product, or modified-release liquid. This route may permit reliance on existing findings for nitrofurantoin while requiring new data for the differences.

A differentiated 505(b)(2) product could target pediatric adherence, feeding-tube administration, reduced dosing burden, or improved storage. The route carries greater development cost and regulatory risk than a conventional ANDA but may provide stronger lifecycle protection.

When does nitrofurantoin oral suspension lose exclusivity?

Nitrofurantoin’s active-ingredient exclusivity expired long ago. The commercial exclusivity analysis therefore centers on product-specific patents, regulatory exclusivity, supply rights, and formulation differentiation rather than new chemical entity protection.

Exclusivity category	Nitrofurantoin oral suspension position
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable to standard UTI use
Biologic exclusivity	Not applicable
Pediatric exclusivity	Product- and study-specific; no general assumption applies
Formulation patent term	Depends on issued claims and filing dates
Orange Book patent protection	Must be evaluated against the current FDA listing for the reference product
Generic entry barrier	Formulation performance, regulatory approval, and commercial supply

A current Orange Book review should be conducted for the specific reference listing and approved labeling. The relevant question is whether the reference product has unexpired, Orange Book-listed patents that could support a Paragraph IV certification challenge. FDA, “Approved Drug Products with Therapeutic Equivalence Evaluations,” is the controlling public source for Orange Book listings (FDA, 2024b).

How many patents cover nitrofurantoin oral suspension?

There is no meaningful patent estate around nitrofurantoin as an active chemical entity. Any current patent count would depend on the specific reference product, formulation owner, jurisdiction, and date of the search.

The practical estate can be divided into four groups:

1. Legacy nitrofurantoin compound patents, which have expired.
2. Product-specific suspension patents, if any are listed for the reference product.
3. Third-party formulation and excipient patents.
4. Delivery-device, packaging, and manufacturing patents.

The most valuable claims would cover a complete formulation with measurable performance advantages. Generic claims such as “nitrofurantoin suspended in an aqueous vehicle” are vulnerable to invalidity and obviousness challenges. Stronger claims could require a defined particle-size distribution, rheological range, sedimentation rate, redispersion time, preservative system, taste-masking component, or tube-administration performance.

Are there Paragraph IV challenges or nitrofurantoin oral suspension lawsuits?

Nitrofurantoin oral suspension is exposed to ANDA competition because the molecule is old and the dosage form is established. A Paragraph IV challenge would be relevant only if an ANDA applicant identified an unexpired Orange Book-listed patent and asserted that the patent was invalid, unenforceable, or not infringed.

No biosimilar litigation applies because nitrofurantoin is not a biologic. No broad patent settlement should be assumed for a mature small-molecule suspension absent a documented court filing or settlement agreement.

Potential litigation issues include:

• Whether the generic suspension has the same pharmaceutical characteristics as the reference product
• Whether a formulation patent is infringed
• Whether a listed patent qualifies for Orange Book listing
• Whether an ANDA applicant’s Paragraph IV notice triggered a 30-month stay
• Whether a settlement restricts launch timing
• Whether a generic product satisfies labeling and dosage-device requirements

For commercial diligence, the primary litigation risk is usually formulation patent enforcement rather than compound patent enforcement.

What commercial opportunities exist for nitrofurantoin oral suspension?

The largest opportunity is a reliable liquid product with better patient usability than the incumbent product.

Pediatric and dysphagia markets

Liquid dosing supports children, adults with dysphagia, patients using enteral feeding tubes, and patients who cannot tolerate capsules. The product must provide accurate low-volume dosing and clear measurement instructions.

An oral syringe-compatible package can reduce dosing errors compared with household teaspoons. Unit-dose cups or prefilled oral syringes could support hospitals, long-term-care facilities, and outpatient pharmacies.

Taste-masked products

Taste masking is a direct commercial differentiator. A product with improved palatability could support adherence without changing the active ingredient or therapeutic indication. The main development challenge is controlling bitterness after swallowing, not merely improving the initial flavor.

Pharmacy-compounded alternative

A commercially manufactured suspension can compete with extemporaneous compounding by offering validated potency, preservative control, labeled stability, and consistent dosing. This is particularly relevant where pharmacies otherwise prepare liquid nitrofurantoin from capsules or bulk material.

Institutional supply

Hospitals, pediatric centers, long-term-care facilities, and home-health providers value:

• Ready-to-use presentation
• Barcoded unit doses
• Oral syringe compatibility
• Reduced preparation time
• Stable refrigerated or room-temperature handling
• Reliable national distribution

Reconstitutable powder

A powder for reconstitution could improve chemical stability and reduce shipping weight. It would introduce new development requirements for wetting, final volume, reconstitution instructions, dose uniformity, and microbial control after reconstitution.

How strong is the patent estate for nitrofurantoin oral suspension?

The patent estate is likely weak at the active-ingredient level and potentially moderate only for a genuinely differentiated formulation. A conventional liquid generic would have limited freedom to charge a premium and would compete primarily on supply reliability, price, and distribution.

Factor	Assessment
Active ingredient patent strength	Very low; legacy molecule
Regulatory exclusivity	Limited
Biosimilar barrier	None
Formulation patent opportunity	Moderate if supported by unexpected performance
Manufacturing barrier	Moderate
Brand loyalty	Limited for a mature antibacterial
Differentiation potential	Moderate through taste, packaging, and dosing
Generic price pressure	High
Supply-chain value	High if incumbent availability is inconsistent

A defensible product should combine formulation know-how with a regulatory and commercial package. The strongest platform would likely include optimized particle engineering, rapid redispersion, validated dose delivery through an oral syringe, improved taste, extended in-use stability, and packaging designed for pediatric and institutional use.

How does nitrofurantoin suspension compare with nitrofurantoin capsules?

Attribute	Oral suspension	Capsules
Administration	Flexible liquid dosing	Fixed-dose solid
Pediatric use	More suitable	Limited by swallowing ability
Dysphagia use	Suitable	Poorer fit
Dose measurement	Requires calibrated device	Premeasured
Taste risk	High	Low during administration
Formulation complexity	High	Lower
Packaging complexity	Higher	Lower
Stability burden	Aqueous suspension and preservative system	Solid-state stability
Manufacturing cost	Generally higher	Generally lower
Commercial differentiation	Taste, device, stability, supply	Price and capsule strength

The suspension should not be positioned as a direct substitute for every capsule prescription. Its most defensible segment is patients who need liquid administration or flexible dosing.

What generic launch scenarios exist?

Scenario 1: Conventional ANDA launch

A generic applicant matches the reference strength and dosage form, satisfies FDA requirements, and competes on price. This creates the highest risk for the incumbent and the lowest commercial margin for new entrants.

Scenario 2: Supply-driven entry

A new manufacturer gains share by maintaining reliable availability during shortages or distributor disruptions. For a mature product, supply reliability can be more valuable than minor formulation improvements.

Scenario 3: Premium liquid differentiation

A 505(b)(2) product introduces improved taste, unit-dose packaging, feeding-tube compatibility, or extended in-use stability. This approach may support higher pricing but requires additional clinical, regulatory, and patent investment.

Scenario 4: Institutional conversion

A supplier targets hospitals and long-term-care providers with oral syringes, barcoding, standardized dosing, and contract supply. The product competes through workflow economics rather than retail branding.

What geographic markets offer the best opportunity?

The United States offers a clear regulatory pathway but has high generic price pressure. European and other regulated markets may offer opportunities where pediatric liquid formulations, pharmacy dispensing, or national supply contracts create local demand. Geographic expansion requires country-specific review of:

• Nitrofurantoin labeling and approved indications
• Pediatric use requirements
• Preservative restrictions
• Excipient acceptability
• Dosing-device standards
• Local reference products
• Patent and supplementary protection certificate status
• Reimbursement and tender pricing

The active ingredient’s age reduces compound-patent risk internationally. Formulation, manufacturing, and packaging claims remain jurisdiction-specific.

What revenue exposure does nitrofurantoin oral suspension create?

The product’s revenue potential depends on volume rather than exclusivity. A conventional generic suspension is likely to face rapid price compression after entry. Revenue improves when the product captures a defined service need, such as pediatric supply, hospital unit dosing, or reliable availability.

The main value drivers are:

1. Market access through an approved reference-equivalent product.
2. Consistent manufacturing and national distribution.
3. Differentiated taste and dosing accessories.
4. Institutional contracts.
5. Lifecycle products using reconstitution or unit-dose packaging.
6. Formulation patents with defensible performance claims.

A formulation-only strategy without a supply or patient-use advantage is unlikely to support durable premium pricing.

Key Takeaways

• Nitrofurantoin oral suspension is a mature small-molecule product with no biosimilar risk and limited active-ingredient exclusivity.
• The commercial reference strength is 25 mg/5 mL.
• The core excipient strategy uses suspending agents, wetting agents, buffers, sweeteners, and flavoring.
• The main technical risks are sedimentation, caking, dose nonuniformity, bitterness, preservative performance, and container compatibility.
• The strongest opportunities are pediatric dosing, dysphagia, feeding-tube administration, unit-dose packaging, and supply reliability.
• A conventional ANDA offers the fastest route but faces high generic price pressure.
• A 505(b)(2) product could create stronger differentiation through taste masking, reconstitution, or administration-device improvements.
• Patent value is more likely to arise from particle engineering, complete formulation performance, manufacturing, or packaging than from nitrofurantoin itself.
• Orange Book and Paragraph IV analysis must be tied to the current reference-product listing and any unexpired listed patents.
• The commercial opportunity is operational and formulation-driven rather than based on molecule-level exclusivity.

FAQs

Can nitrofurantoin oral suspension be administered through a feeding tube?

A feeding-tube product requires dedicated compatibility, dose-recovery, clogging, and adsorption studies. The approved label should control administration instructions unless a product has supporting data for tube delivery.

What concentration is commercially established for nitrofurantoin liquid?

The established U.S. oral suspension concentration is 25 mg/5 mL, equivalent to 5 mg/mL (FDA, 2024a).

Is nitrofurantoin oral suspension a biologic?

No. Nitrofurantoin is a small-molecule antibacterial. FDA approval of a follow-on product would proceed through a generic or 505(b)(2) pathway, not the biosimilar pathway.

Which excipient presents the greatest formulation risk?

The suspending system presents the greatest combined technical risk because it affects sedimentation, redispersion, pourability, syringeability, and dose uniformity. The flavor system is the leading patient-acceptance risk.

Can a new nitrofurantoin suspension obtain formulation patent protection?

Yes, but protection requires claims directed to a novel and defensible formulation, process, particle-size profile, delivery system, or measurable performance advantage. A conventional mixture of known excipients is unlikely to provide strong exclusivity.

References

1. U.S. Food and Drug Administration. (2024a). Furadantin: Nitrofurantoin oral suspension, USP prescribing information. FDA-approved labeling.

2. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

3. United States Pharmacopeia. (2024). General chapter <51>: Antimicrobial effectiveness testing. United States Pharmacopeial Convention.

4. United States Pharmacopeia. (2024). General chapter <911>: Viscosity. United States Pharmacopeial Convention.